Tristan McIntosh1, Sumit Mohan2,3,4, Deirdre Sawinski5, Ana Iltis6,7, James M DuBois1. 1. Division of General Medical Sciences, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA. 2. Division of Nephrology, Department of Medicine Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA. 3. Department of Epidemiology, Columbia University, Mailman School of Public Health, New York, NY, USA. 4. Columbia University Renal Epidemiology (CURE) Group, New York, NY, USA. 5. Renal, Electrolyte and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 6. Department of Philosophy, Wake Forest University, Winston Salem, NC, USA. 7. Center for Bioethics Health and Society, Wake Forest University, Winston Salem, NC, USA.
Abstract
INTRODUCTION: Tests exist for ApoL1 genetic variants to determine whether a potential donor's kidneys are at increased risk of kidney failure. Variants of the ApoL1 gene associated with increased risk are primarily found in people with West African ancestry. Given uncertainty about clinical implications of ApoL1 test results for living kidney donors and recipients and the lack of uniform guidelines for ApoL1 testing, transplant centers across the United States vary in ApoL1 testing practices. RESEARCH QUESTIONS: (1) What approach do transplant centers take to determine whether prospective donors are of West African ancestry? (2)How do transplant centers engage potential donors during the ApoL1 testing process? (3) What do transplant centers identify as concerns and barriers to ApoL1 testing? and (4) What actions do transplant centers take when a potential donor has 2 ApoL1 risk variants? DESIGN: We explored the current practices of transplant centers by surveying nephrologists and transplant surgeons at transplant centers evaluating the majority of black living donors in the United States. RESULTS: About half of these transplant centers offered ApoL1 testing. Of those who offered ApoL1 testing, only half involved the donor in decision-making about donation when the donor has 2 risk variants. DISCUSSION: Unaddressed differences in the priorities of transplant centers and black living donors may stigmatize black donors and undermine trust in the health-care and organ donation systems. Variation in transplant center testing practices points to the critical need for further research and community engagement to inform the development of guidelines for ApoL1 testing.
INTRODUCTION: Tests exist for ApoL1 genetic variants to determine whether a potential donor's kidneys are at increased risk of kidney failure. Variants of the ApoL1 gene associated with increased risk are primarily found in people with West African ancestry. Given uncertainty about clinical implications of ApoL1 test results for living kidney donors and recipients and the lack of uniform guidelines for ApoL1 testing, transplant centers across the United States vary in ApoL1 testing practices. RESEARCH QUESTIONS: (1) What approach do transplant centers take to determine whether prospective donors are of West African ancestry? (2)How do transplant centers engage potential donors during the ApoL1 testing process? (3) What do transplant centers identify as concerns and barriers to ApoL1 testing? and (4) What actions do transplant centers take when a potential donor has 2 ApoL1 risk variants? DESIGN: We explored the current practices of transplant centers by surveying nephrologists and transplant surgeons at transplant centers evaluating the majority of black living donors in the United States. RESULTS: About half of these transplant centers offered ApoL1 testing. Of those who offered ApoL1 testing, only half involved the donor in decision-making about donation when the donor has 2 risk variants. DISCUSSION: Unaddressed differences in the priorities of transplant centers and black living donors may stigmatize black donors and undermine trust in the health-care and organ donation systems. Variation in transplant center testing practices points to the critical need for further research and community engagement to inform the development of guidelines for ApoL1 testing.
Entities:
Keywords:
ApoL1; ethics; kidney transplant; living organ donors; transplant center
Authors: Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak Journal: Science Date: 2010-07-15 Impact factor: 47.728
Authors: Carl D Langefeld; Mary E Comeau; Maggie C Y Ng; Meijian Guan; Latchezar Dimitrov; Poorva Mudgal; Mitzie H Spainhour; Bruce A Julian; Jeffrey C Edberg; Jennifer A Croker; Jasmin Divers; Pamela J Hicks; Donald W Bowden; Gary C Chan; Lijun Ma; Nicholette D Palmer; Robert P Kimberly; Barry I Freedman Journal: Kidney Int Date: 2018-06-07 Impact factor: 10.612
Authors: David M Cohen; Anuja Mittalhenkle; David L Scott; Carlton J Young; Douglas J Norman Journal: Transplantation Date: 2011-10-15 Impact factor: 4.939
Authors: A M Reeves-Daniel; J A DePalma; A J Bleyer; M V Rocco; M Murea; P L Adams; C D Langefeld; D W Bowden; P J Hicks; R J Stratta; J-J Lin; D F Kiger; M D Gautreaux; J Divers; B I Freedman Journal: Am J Transplant Date: 2011-04-12 Impact factor: 8.086
Authors: Mona D Doshi; Mariella Ortigosa-Goggins; Amit X Garg; Lihua Li; Emilio D Poggio; Cheryl A Winkler; Jeffrey B Kopp Journal: J Am Soc Nephrol Date: 2018-01-16 Impact factor: 10.121
Authors: Jae-Hyung Chang; S Ali Husain; Dominick Santoriello; Michael B Stokes; Clifford D Miles; Kirk W Foster; Yifu Li; Leigh-Anne Dale; Russell J Crew; David J Cohen; Krzysztof Kiryluk; Ali G Gharavi; Sumit Mohan Journal: Am J Kidney Dis Date: 2018-07-25 Impact factor: 8.860
Authors: Elisa J Gordon; Daniela Amόrtegui; Isaac Blancas; Catherine Wicklund; John Friedewald; Richard R Sharp Journal: Am J Kidney Dis Date: 2018-10-22 Impact factor: 8.860
Authors: Jordan G Nestor; Amber J Li; Kristen L King; S Ali Husain; Tristan J McIntosh; Deirdre Sawinski; Ana S Iltis; Melody S Goodman; Heidi A Walsh; James M DuBois; Sumit Mohan Journal: Clin Transplant Date: 2021-10-28 Impact factor: 3.456
Authors: Mona D Doshi; Elisa J Gordon; Barry I Freedman; Craig Glover; Jayme E Locke; Christie P Thomas Journal: Transplantation Date: 2021-10-01 Impact factor: 4.939
Authors: Barry I Freedman; Wylie Burke; Jasmin Divers; Lucy Eberhard; Crystal A Gadegbeku; Rasheed Gbadegesin; Michael E Hall; Tiffany Jones-Smith; Richard Knight; Jeffrey B Kopp; Csaba P Kovesdy; Keith C Norris; Opeyemi A Olabisi; Glenda V Roberts; John R Sedor; Erika Blacksher Journal: J Am Soc Nephrol Date: 2021-04-14 Impact factor: 14.978
Authors: Christine Park; Mandisa-Maia Jones; Samantha Kaplan; Felicitas L Koller; Julius M Wilder; L Ebony Boulware; Lisa M McElroy Journal: Int J Equity Health Date: 2022-02-12